37 patents
Utility
DLL3 binding proteins and methods of use
7 Nov 23
Provided herein are DLL3 binding proteins and DLL3 targeting multispecific proteins (e.g., DLL3 targeting trispecific protein) comprising a domain binding to CD3, a half-life extension domain, and a domain binding to DLL3 (such as a DLL3 binding protein as provided herein).
Holger Wesche, Richard J. Austin
Filed: 21 Aug 20
Utility
Single Domain Serum Albumin Binding Protein
17 Aug 23
Disclosed herein are single domain serum albumins binding proteins with improved thermal stability, binding affinities, and robust aggregation profiles.
Robert B. DUBRIDGE, Bryan D. LEMON, Richard J. AUSTIN, Luke EVNIN, Jeanmarie GUENOT
Filed: 19 Sep 22
Utility
Single chain variable fragment CD3 binding proteins
11 Apr 23
Disclosed herein are single chain variable fragment CD3 binding proteins with improved binding affinities, and robust aggregation profiles.
Robert B. Dubridge, Pui Seto, Richard J. Austin, Luke Evnin, Jeanmarie Guenot, Bryan Lemon
Filed: 27 Jan 20
Utility
Mesothelin binding proteins
21 Mar 23
Disclosed herein are MSLN binding proteins with improved binding affinities and improved ability to mediate T cell dependent killing of cancer cells expressing mesothelin.
Holger Wesche, Bryan D. Lemon, Richard J. Austin, Robert B. Dubridge
Filed: 27 Jan 20
Utility
Inducible monovalent antigen binding protein
27 Dec 22
Disclosed herein are inducible monovalent target-binding proteins which are activated upon protease cleavage.
Patrick Baeuerle, Holger Wesche
Filed: 28 Feb 18
Utility
Single domain serum albumin binding protein
27 Sep 22
Disclosed herein are single domain serum albumins binding proteins with improved thermal stability, binding affinities, and robust aggregation profiles.
Robert B. Dubridge, Bryan D. Lemon, Richard J. Austin, Luke Evnin, Jeanmarie Guenot
Filed: 16 Oct 18
Utility
Epcam Binding Proteins and Methods of Use
25 Aug 22
Provided herein are EpCAM binding proteins, pharmaceutical compositions comprising such proteins or fragments thereof, as well as nucleic acids, recombinant expression vectors and host cells for making such EpCAM binding proteins.
Holger WESCHE, Richard J. AUSTIN, Shuoyen Jack LIN, Bryan LEMON, Kevin WRIGHT, Sony ROCHA, Kathryn KWANT
Filed: 14 May 20
Utility
Trispecific Proteins and Methods of Use
14 Apr 22
Provided herein are B cell maturation agent (BCMA) targeting trispecific proteins comprising a domain binding to CD3, a half-life extension domain, and a domain binding to BCMA.
Holger WESCHE, Bryan D. LEMON, Richard J. AUSTIN
Filed: 14 Sep 21
Utility
FLT3 Binding Proteins and Methods of Use
31 Mar 22
Provided herein are FLT3 binding proteins, pharmaceutical compositions comprising such proteins or fragments thereof, as well as nucleic acids, recombinant expression vectors and host cells for making such FLT3 binding proteins.
Holger WESCHE, Richard J. AUSTIN
Filed: 12 Oct 21
Utility
Conditionally Active Receptors
24 Feb 22
Disclosed herein are conditionally active receptors which comprise a target antigen binding domain and a binding moiety.
Shuoyen Jack LIN, Richard J. AUSTIN, Bryan D. LEMON, Kevin WRIGHT, Holger WESCHE
Filed: 14 May 19
Utility
Egfr Binding Proteins and Methods of Use
20 Jan 22
Provided herein are EGFR binding proteins and EGFR targeting trispecific proteins comprising a domain binding to CD3, a half-life extension domain, and a domain binding to EGFR.
Holger WESCHE, Richard J. AUSTIN
Filed: 20 Sep 19
Utility
FLT3 binding proteins and methods of use
23 Nov 21
Provided herein are FLT3 binding proteins, pharmaceutical compositions comprising such proteins or fragments thereof, as well as nucleic acids, recombinant expression vectors and host cells for making such FLT3 binding proteins.
Holger Wesche, Richard J. Austin
Filed: 19 Feb 21
Utility
Conditionally Activated Target-binding Molecules
18 Nov 21
Disclosed herein are conditionally active multivalent target-binding proteins which comprise two binding moieties, two linkers, two target antigen binding domains, and a constant domain.
Shuoyen Jack LIN, Holger WESCHE, Kathryn KWANT
Filed: 20 Sep 19
Utility
Trispecific proteins and methods of use
5 Oct 21
Provided herein are B cell maturation agent (BCMA) targeting trispecific proteins comprising a domain binding to CD3, a half-life extension domain, and a domain binding to BCMA.
Holger Wesche, Bryan D. Lemon, Richard J. Austin
Filed: 12 Oct 18
Utility
Binding Moiety for Conditional Activation of Immunoglobulin Molecules
23 Sep 21
Disclosed herein are binding moieties that comprise non-CDR loops for masking the binding of a binding molecule to its target and CDRs for binding bulk serum proteins.
Shuoyen Jack LIN, Richard J. AUSTIN, Bryan D. LEMON, Kathryn KWANT, Sony S. ROCHA, Holger WESCHE
Filed: 14 May 19
Utility
Dual Binding Moiety
16 Sep 21
Disclosed herein is a dual binding moiety that comprises non-CDR loops for masking the binding of a domain, such as a target antigen binding domain to its target, by steric occlusion and specific masking, and CDRs for binding bulk serum proteins.
Shuoyen Jack LIN, Richard J. AUSTIN, Bryan D. LEMON, Holger WESCHE
Filed: 14 May 19
Utility
Conditionally Activated Binding Protein Comprising a Sterically Occluded Target Binding Domain
2 Sep 21
Disclosed herein is a conditionally active target binding protein that contains a first binding domain that binds to a bulk serum protein and sterically occludes binding of a second binding domain to its target.
Shuoyen Jack LIN, Richard J. AUSTIN, Bryan D. LEMON, Holger WESCHE
Filed: 14 May 19
Utility
FLT3 Binding Proteins and Methods of Use
26 Aug 21
Provided herein are FLT3 binding proteins, pharmaceutical compositions comprising such proteins or fragments thereof, as well as nucleic acids, recombinant expression vectors and host cells for making such FLT3 binding proteins.
Holger WESCHE, Richard J. AUSTIN
Filed: 19 Feb 21
Utility
Trispecific Binding Proteins and Methods of Use
17 Jun 21
Provided herein are trispecific antigen-binding proteins comprising a domain binding to CD3, a half-life extension domain, and a domain binding to a target antigen.
Patrick BAEUERLE, Luke EVNIN, Jeanmarie GUENOT, Vanitha RAMAKRISHNAN, Holger WESCHE
Filed: 2 Feb 21
Utility
B Cell Maturation Antigen Binding Proteins
10 Jun 21
Disclosed herein are B cell maturation antigen binding proteins with improved binding affinities and improved ability to mediate killing of cancer cells expressing B cell maturation antigen (BCMA).
Holger WESCHE, Bryan D. LEMON, Richard J. AUSTIN
Filed: 15 Jan 21